The European Medicines Agency (EMA) convened its Medicine Shortages Working Party on June 17, 2025, addressing urgent challenges in the supply of essential medicinal products across the continent. The virtual meeting, chaired by Monica Dias, focused on evaluating current shortages and strategizing preventive measures to ensure uninterrupted access to vital medications for both human and veterinary use.
Addressing Current Supply Challenges
Participants reviewed the status of ongoing shortages, including critical shortages of insulin, GLP-1 receptor agonists, and essential medications like naloxegol and praziquantel. Discussions highlighted the strategic importance of these drugs and the potential impact on patient care. The working party also examined the effectiveness of the voluntary solidarity mechanism (VSM) in mitigating shortages and explored national measures implemented to address these crises.
Strategic Actions and Future Preparedness
The meeting delved into the potential repercussions of the international situation on medicine supply chains. Feedback from subgroup analyses on crisis monitoring and preparedness was presented, emphasizing the necessity for robust contingency plans. Updates on the availability of antibiotics and other critical medicines were provided, underscoring the agency’s commitment to proactive management of supply vulnerabilities.
- Insufficient insulin supplies could lead to severe health risks for diabetic patients if not promptly addressed.
- The discontinuation of key products like Moventig CAP and Biltricide NAP highlights gaps in the current supply chain resilience.
- National mitigation strategies vary significantly, indicating a need for a more unified EU-wide approach.
The Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) shared insights from their latest meeting, presenting recommendations to bolster the supply of anti-D immunoglobulin and refining vulnerability assessment methodologies. Collaborative efforts with the Global Regulatory Working Group on Drug Shortages were also discussed, aiming to harmonize responses on a global scale.
Ensuring the continuous availability of critical medicines remains a top priority for the EMA. The agency is exploring further collaborations with pharmaceutical companies and national health authorities to enhance supply chain transparency and responsiveness. Upcoming meetings are scheduled to maintain momentum in addressing these urgent shortages.
EMA’s proactive stance in tackling medicine shortages demonstrates its dedication to safeguarding public health. By systematically addressing current gaps and enhancing preparedness strategies, the agency aims to mitigate the impact of future supply disruptions. Stakeholders are encouraged to engage in ongoing dialogue and contribute to developing sustainable solutions for medicine availability across Europe.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
